Cumberland Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Cumberland Pharmaceuticals Inc. (CPIX) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$1.06 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-22.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2020-12-10
- Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was -$1.06M.
- Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-12-31 was -$960.71K.
- Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-09-30 was -$1.95M.
- Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-06-30 was -$549.51K.
- Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2016 was -$944.68K, a 229.17% decline from fiscal 2015.
- Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2015 was $731.35K, a 69.83% decline from fiscal 2014.
- Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2014 was $2.42M.
- Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2013 was -$2.10M, a 136.02% decline from fiscal 2012.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$1.06M 10-Q · filed 2020-05-22 | -$2.02M derived: sum of 2 quarters · filed 2020-12-10 | -$3.97M derived: sum of 3 quarters · filed 2020-12-10 | -$4.52M derived: sum of 4 quarters · filed 2020-12-10 |
| 2019-12-31 | -$960.71K derived: 8-K 12 month − 10-Q 9 month · filed 2020-12-10 | -$2.91M derived: sum of 2 quarters · filed 2020-12-10 | -$3.46M derived: sum of 3 quarters · filed 2020-12-10 | -$3.54M 8-K · filed 2020-12-10 |
| 2019-09-30 | -$1.95M 10-Q · filed 2019-11-13 | -$2.50M derived: sum of 2 quarters · filed 2019-11-13 | -$2.58M 10-Q · filed 2019-11-13 | -$4.80M derived: sum of 4 quarters · filed 2020-12-10 |
| 2019-06-30 | -$549.51K 10-Q · filed 2019-08-14 | -$623.38K 10-Q · filed 2019-08-14 | -$2.84M derived: sum of 3 quarters · filed 2020-12-10 | -$4.49M derived: sum of 4 quarters · filed 2020-12-10 |
| 2019-03-31 | -$73.88K 10-Q · filed 2020-05-22 | -$2.29M derived: sum of 2 quarters · filed 2020-12-10 | -$3.94M derived: sum of 3 quarters · filed 2020-12-10 | -$4.66M derived: sum of 4 quarters · filed 2020-12-10 |
| 2018-12-31 | -$2.22M derived: 8-K 12 month − 10-Q 9 month · filed 2020-12-10 | -$3.86M derived: sum of 2 quarters · filed 2020-12-10 | -$4.58M derived: sum of 3 quarters · filed 2020-12-10 | -$6.96M 8-K · filed 2020-12-10 |
| 2018-09-30 | -$1.64M 10-Q · filed 2019-11-13 | -$2.36M derived: sum of 2 quarters · filed 2019-11-13 | -$4.74M 10-Q · filed 2019-11-13 | -$5.54M derived: sum of 4 quarters · filed 2020-12-10 |
| 2018-06-30 | -$720.69K 10-Q · filed 2019-08-14 | -$3.10M 10-Q · filed 2019-08-14 | -$3.90M derived: sum of 3 quarters · filed 2020-12-10 | -$4.64M derived: sum of 4 quarters · filed 2020-12-10 |
| 2018-03-31 | -$2.38M 10-Q · filed 2019-05-15 | -$3.18M derived: sum of 2 quarters · filed 2020-12-10 | -$3.92M derived: sum of 3 quarters · filed 2020-12-10 | -$9.08M derived: sum of 4 quarters · filed 2020-12-10 |
| 2017-12-31 | -$800.54K derived: 8-K 12 month − 10-Q 9 month · filed 2020-12-10 | -$1.54M derived: sum of 2 quarters · filed 2020-12-10 | -$6.70M derived: sum of 3 quarters · filed 2020-12-10 | -$7.98M 8-K · filed 2020-12-10 |
| 2017-09-30 | -$743.03K 10-Q · filed 2018-11-14 | -$5.90M derived: sum of 2 quarters · filed 2018-11-14 | -$7.18M 10-Q · filed 2018-11-14 | -$7.93M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | -$5.16M 10-Q · filed 2018-08-14 | -$6.44M 10-Q · filed 2018-08-14 | -$7.18M derived: sum of 3 quarters · filed 2019-03-12 | -$7.08M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | -$1.27M 10-Q · filed 2018-05-09 | -$2.02M derived: sum of 2 quarters · filed 2019-03-12 | -$1.92M derived: sum of 3 quarters · filed 2019-03-12 | -$1.97M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$749.69K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$643.53K derived: sum of 2 quarters · filed 2019-03-12 | -$691.57K derived: sum of 3 quarters · filed 2019-03-12 | -$944.68K 10-K · filed 2019-03-12 |
| 2016-09-30 | $106.17K 10-Q · filed 2017-11-08 | $58.12K derived: sum of 2 quarters · filed 2017-11-08 | -$194.99K 10-Q · filed 2017-11-08 | -$43.93K derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | -$48.04K 10-Q · filed 2017-08-09 | -$301.15K 10-Q · filed 2017-08-09 | -$150.10K derived: sum of 3 quarters · filed 2018-03-09 | -$23.48K derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | -$253.11K 10-Q · filed 2017-05-15 | -$102.05K derived: sum of 2 quarters · filed 2018-03-09 | $24.56K derived: sum of 3 quarters · filed 2018-03-09 | $430.56K derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | $151.06K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $277.67K derived: sum of 2 quarters · filed 2018-03-09 | $683.67K derived: sum of 3 quarters · filed 2018-03-09 | $731.35K 10-K · filed 2018-03-09 |
| 2015-09-30 | $126.61K 10-Q · filed 2016-11-03 | $532.61K derived: sum of 2 quarters · filed 2016-11-03 | $580.29K 10-Q · filed 2016-11-03 | $1.25M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | $406.00K 10-Q · filed 2016-08-05 | $452.28K 10-Q · filed 2016-08-05 | $1.12M derived: sum of 3 quarters · filed 2017-03-13 | $1.87M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-03-31 | $46.28K 10-Q · filed 2016-05-13 | $715.19K derived: sum of 2 quarters · filed 2017-03-13 | $1.46M derived: sum of 3 quarters · filed 2017-03-13 | $2.18M derived: sum of 4 quarters · filed 2017-03-13 |
| 2014-12-31 | $668.91K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $1.41M derived: sum of 2 quarters · filed 2017-03-13 | $2.14M derived: sum of 3 quarters · filed 2017-03-13 | $2.42M 10-K · filed 2017-03-13 |
| 2014-09-30 | $745.92K 10-Q · filed 2015-11-06 | $1.47M derived: sum of 2 quarters · filed 2015-11-06 | $1.75M 10-Q · filed 2015-11-06 | $254.45K derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $722.57K 10-Q · filed 2015-08-07 | $1.01M 10-Q · filed 2015-08-07 | -$491.47K derived: sum of 3 quarters · filed 2016-03-14 | -$1.31M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $286.32K 10-Q · filed 2015-05-15 | -$1.21M derived: sum of 2 quarters · filed 2016-03-14 | -$2.03M derived: sum of 3 quarters · filed 2016-03-14 | |
| 2013-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$2.32M derived: sum of 2 quarters · filed 2016-03-14 | -$2.10M 10-K · filed 2016-03-14 | |
| 2013-09-30 | -$819.94K 10-Q · filed 2014-11-07 | -$604.25K 10-Q · filed 2014-11-07 | ||
| 2012-12-31 | $5.84M 10-K · filed 2015-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |